They showed that low levels of exogenous E2F1 promote proliferation, moderate levels induce cell cycle arrest, and very high levels promote apoptosis, thus they suggested that targeting E2F1 for upregulation may represent an attractive therapeutic strategy in cancer. Here, E2F1 is linked to cancer.